We came across an RRM2-specific inhibitor triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone), a drug reportedly effective in two clinical studies on cervical cancer35 and currently assessed in several phase I and II trials in other cancer types (https://clinicaltrials.gov/ct2/results?term=triapine). The gene discussed is RRM2; the disease is cancer.